Enanta Pharmaceuticals FQ3 beats on fewer losses

Enanta Pharmaceuticals (ENTA +6%) moves up after beating FQ3 estimates earlier this morning.

EPS losses came in at $0.23 per share, on revenues of $1.6M.

Analysts expected loss per share of $0.31.

In the same period last year, net loss was $3.5M, or $4.31 per share, on revenues of $2.5M.

Cash and equivalents totaled $114.8M at the end of June, compared to $45.4M on September 30, 2012.

The company expects that its current cash, cash equivalents and marketable securities will be sufficient to meet anticipated requirements for at least the next 24 months.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs